文献速递中枢神经肿瘤放疗放疗物理与技术

胶质母细胞瘤容积旋转调强放疗正常组织保护的单中心临床经验

Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience.
PubMed 文献 · Radiat Oncol · 2017-05-02

该单中心研究比较45例胶质母细胞瘤患者采用VMAT与45例采用IMRT的临床治疗计划,两者靶区覆盖相似(PTV至少95%覆盖,boost PTV中位平均剂量差仅0.1 Gy),VMAT在脑干和耳蜗保护上更优,治疗时间缩短5分钟。

要点

  • VMAT与IMRT靶区覆盖相似,boost PTV中位平均剂量差仅0.1 Gy。
  • VMAT脑干中位平均剂量较IMRT低9.4 Gy,双侧耳蜗剂量更低。
  • VMAT总治疗时间缩短5分钟,可能改善临床效率。

核心结论

  • VMAT用于胶质母细胞瘤可提供与IMRT相似的靶区覆盖,脑干和耳蜗保护更优,治疗时间更短。

研究设计与样本

  • 单中心临床经验分析,纳入VMAT和IMRT患者队列各45例,比较90例临床治疗计划的靶区覆盖和危及器官剂量。

主要发现

  • 所有计划PTV覆盖至少95%,IMRT与VMAT的boost PTV中位平均剂量仅差0.1 Gy。
  • VMAT脑干中位平均剂量较IMRT低9.4 Gy。
  • VMAT同侧耳蜗平均剂量低19.7 Gy,对侧耳蜗低9.5 Gy。
  • VMAT总治疗时间缩短5分钟。
  • 同侧海马D100%差异为12 Gy,但P=0.03未达统计学显著。

关键数值与推荐

  • PTV处方剂量50 Gy分30次,同步整合boost PTV处方剂量60 Gy。

临床怎么用

  • 基于本中心经验,VMAT治疗胶质母细胞瘤不劣于IMRT,尤其可能适用于需再程放疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with glioblastoma multiforme (GBM) require radiotherapy as part of definitive management. Our institution has adopted the use of volumetric arc therapy (VMAT) due to superior sparing of the adjacent organs at risk (OARs) compared to intensity modulated radiation therapy (IMRT). Here we report our clinical experience by analyzing target coverage and sparing of OARs for 90 clinical treatment plans. METHODS: VMAT and IMRT patient cohorts comprising 45 patients each were included in this study. For all patients, the planning target volume (PTV) received 50 Gy in 30 fractions, and the simultaneous integrated boost PTV received 60 Gy. The characteristics of the two patient cohorts were examined for similarity. The doses to target volumes and OARs, including brain, brainstem, hippocampi, optic nerves, eyes, and cochleae were then compared using statistical analysis. Target coverage and normal tissue sparing for six patients with both clinical IMRT and VMAT plans were analyzed. RESULTS: PTV coverage of at least 95% was achieved for all plans, and the median mean dose to the boost PTV differed by only 0.1 Gy between the IMRT and VMAT plans. Superior sparing of the brainstem was found with VMAT, with a median difference in mean dose being 9.4 Gy. The ipsilateral cochlear mean dose was lower by 19.7 Gy, and the contralateral cochlea was lower by 9.5 Gy. The total treatment time was reduced by 5 min. The difference in the ipsilateral hippocampal D100% was 12 Gy, though this is not statistically significant (P = 0.03). CONCLUSIONS: VMAT for GBM patients can provide similar target coverage, superior sparing of the brainstem and cochleae, and be delivered in a shorter period of time compared with IMRT. The shorter treatment time may improve clinical efficiency and the quality of the treatment experience. Based on institutional clinical experience, use of VMAT for the treatment of GBMs appears to offer no inferiority in comparison to IMRT and may offer distinct advantages, especially for patients who may require re-irradiation.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Briere TM, McAleer MF, Levy LB, et al. Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience. Radiat Oncol. 2017. PMID: 28464840. doi:10.1186/s13014-017-0810-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。